Quiz
The Impact of HS Diagnosis on Comorbidity Burden
News
08/18/2026
Rebecca Amrick
A systematic review of clinical trials examining the impact of Janus kinase (JAK) inhibitors on skin conditions found that they demonstrated higher efficacy and comparable safety when compared with a placebo.
A systematic review of clinical trials examining the impact of Janus kinase (JAK) inhibitors on skin conditions found that they demonstrated higher efficacy and comparable safety when compared with a placebo.
A systematic review of clinical...
08/18/2026
First Report Managed Care
News
12/20/2023
Lisa Kuhns, PhD, MD
“Although North American guidelines for HS management were recently published in 2019 from both the United States and Canadian HS Foundations, barriers to HS expertise among dermatologists still exist,” wrote coauthors.
“Although North American guidelines for HS management were recently published in 2019 from both the United States and Canadian HS Foundations, barriers to HS expertise among dermatologists still exist,” wrote coauthors.
“Although North American...
12/20/2023
First Report Managed Care
News
09/20/2023
Jolynn Tumolo
“Patients with HS may require comprehensive care strategies involving a multidisciplinary team of physicians to improve health while reducing health care expenditures,” researchers advised.
“Patients with HS may require comprehensive care strategies involving a multidisciplinary team of physicians to improve health while reducing health care expenditures,” researchers advised.
“Patients with HS may require...
09/20/2023
First Report Managed Care
News
08/31/2023
Danielle Sposato
Hidradenitis suppurativa treatment involves pharmacological and surgical options, but systemic treatment is restricted, with only adalimumab, an anti-TNF-a antibody, approved.
Hidradenitis suppurativa treatment involves pharmacological and surgical options, but systemic treatment is restricted, with only adalimumab, an anti-TNF-a antibody, approved.
Hidradenitis suppurativa...
08/31/2023
First Report Managed Care